B
Bull
Bull · 25%PHVS
$32.16
Precio del escenario
$35.320
-1.604 (-4.54%)Al cierre
Loading chart…
- High
- 37.405
- Open
- 37.000
- VWAP
- 35.99
- Vol
- 479.03K
- Mkt Cap
- 969.24M
- Low
- 35.260
- Amount
- 17.24M
- EV/EBITDA, TTM
- 0.00
Pharvaris NV is a Netherlands-based company primarily engaged in the biopharmaceutical industry. The Company focuses on developing oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks. Their key product is Deucrictibant (PHA121, PHA-022121), which is a small-molecule bradykinin B2 receptor antagonist. It is intended for both the on-demand and prophylactic treatment of HAE attacks. Deucrictibant has been studied in vitro, ex vivo, and in vivo models to assess its effectiveness in blocking the bradykinin B2 receptor. The Company is developing deucrictibant for on-demand use as PHVS416, a softgel capsule, and for prophylactic use as PHVS719, an extended-release tablet.
AI analysis of Pharvaris NV (PHVS)
holdPharvaris NV is currently a hold. The stock is priced at $35.32, with a recent RSI of 36.83 indicating it may be oversold. However, the company has reported significant losses, with a net income of -39,200,673 EUR in Q1 2026, and the forward P/E ratio is currently at 0, suggesting no earnings expectations in the near term. The recent insider selling of 37,600 shares by an executive may also raise concerns among investors. While there is potential for growth with a price target of $55 from Wells Fargo, the risks of continued losses and insider sentiment should be considered before making a buy decision.
Métricas de valoración
The current forward P/E ratio for Pharvaris NV (PHVS) is 0.00, compared to its 5-year average forward P/E of -6.59.
Alphio AI Price Scenarios for PHVS
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding PHVS
Cronología de eventos
Noticias
5.007-24FoolPharvaris Executive Sells 37,600 Shares Amid Strong Market Performance
5.007-24NASDAQ.COMSchikan Sells 37,600 Shares of Pharvaris for $1.33 Million
6.007-15CNBCLatest Ratings and Price Target Adjustments on Wall Street
9.007-06NASDAQ.COMPharvaris' NDA for Deucrictibant Accepted by FDA
- 9.007-06NASDAQ.COM
Pharvaris' New Drug Application Accepted by FDA for Deucrictibant
PHVS FAQ — answered by Alphio AI
Pharvaris NV is a Netherlands-based company primarily engaged in the biopharmaceutical industry. The Company focuses on developing oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks. Their key product is Deucrictibant (PHA121, PHA-022121), which is a small-molecule bradykinin B2 receptor antagonist. It is intended for both the on-demand and prophylactic treatment of HAE attacks. Deucrictibant has been studied in vitro, ex vivo, and in vivo models to assess its effectiveness in blocking the bradykinin B2 receptor. The Company is developing deucrictibant for on-demand use as PHVS416, a softgel capsule, and for prophylactic use as PHVS719, an extended-release tablet. It operates in the Healthcare sector.
Pharvaris NV is currently a hold. The stock is priced at $35.32, with a recent RSI of 36.83 indicating it may be oversold. However, the company has reported significant losses, with a net income of -39,200,673 EUR in Q1 2026, and the forward P/E ratio is currently at 0, suggesting no earnings expectations in the near term. The recent insider selling of 37,600 shares by an executive may also raise concerns among investors. While there is potential for growth with a price target of $55 from Wells Fargo, the risks of continued losses and insider sentiment should be considered before making a buy decision.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.